China’s indigenously developed COVID-19 vaccines set to surprise the world: GlobalData
China's Sinopharm and Sinovac (in collaboration with Brazil-based Butantan) have both reported encouraging results in the early phases of human testing for COVID-19
China is among the leading countries that are aggressively involved in developing vaccines for COVID-19, with one vaccine each from Sinopharm Group and Sinovac Biotech entering Phase 3 clinical development. The progress made by Chinese pharma companies in recent weeks indicates that they can surprise the world with their success in terms of the launch plan, says GlobalData, a leading data and analytics company.
Sinopharm and Sinovac (in collaboration with Brazil-based Butantan) have both reported encouraging results in the early phases of human testing for COVID-19. They now plan to test their vaccines in Phase 3 with a larger study population, at different locations across the globe.
Krishna Srinivasaraghavan, Pharma Analyst at GlobalData, says, “With the growing number of COVID-19 infections and deaths across the globe, it is necessary to have a safe and effective vaccine as soon as possible to control the pandemic. However, there are no approved vaccines that are currently available.
“Vaccines from AstraZeneca, Moderna and Pfizer are the most talked about currently and are leading the vaccine development space. However, Chinese vaccines are equally progressing